PedAM

Pediatric Disease Annotations & Medicines


	back pain

Disease ID	1928
Disease	back pain
Definition	Acute or chronic pain located in the posterior regions of the THORAX; LUMBOSACRAL REGION; or the adjacent regions.
Synonym	unspecified ache back ache, back aches back aches, back and back pain back ache back aches back over pain back pain (disorder) back pain (finding) back pain - finding back pain [disease/finding] back pain in back pain over back pain, unspecified back paining back pains backache backache (disorder) backache (finding) backache - disorder backache - finding backache nos backache symptom backache symptom (finding) backache symptom nos backache symptom nos (disorder) backache symptom nos (finding) backache symptoms backache, nos backache, unspecified backache, unspecified (disorder) backache, unspecified (finding) backaches backpain backs pain dorsal back pain dorsal pain dorsalgia dorsalgia (finding) dorsalgia unspecified dorsodynia notalgia pain back pain dorsal pain in back pain over the back pain, back pains, back unspecified back pain
UMLS	C0004604
MeSH	D001416
SNOMED-CT	SNOMEDCT_US_2016_09_01:161891005
Comorbidity	UMLS \| Disease \| Sentences' Count(Total Sentences:112) C0011570 \| depression \| 30 C0158266 \| disc degeneration \| 24 C0700594 \| radiculopathy \| 22 C0029456 \| osteoporosis \| 12 C0158266 \| intervertebral disc degeneration \| 10 C0003864 \| arthritis \| 10 C0158266 \| degenerative disc disease \| 10 C0037317 \| sleep disturbance \| 9 C0037944 \| spinal stenosis \| 8 C0949690 \| spondyloarthritis \| 8 C0028754 \| obesity \| 8 C0038016 \| spondylolisthesis \| 7 C0036439 \| scoliosis \| 7 C0029408 \| osteoarthritis \| 6 C0003467 \| anxiety \| 6 C0038012 \| spondylitis \| 6 C0003486 \| aortic aneurysm \| 5 C0041296 \| tuberculosis \| 4 C0038019 \| spondylosis \| 4 C0038013 \| ankylosing spondylitis \| 4 C0036440 \| idiopathic scoliosis \| 4 C0022821 \| kyphosis \| 4 C0016053 \| fibromyalgia \| 4 C0038018 \| spondylolysis \| 4 C0003873 \| rheumatoid arthritis \| 4 C0162871 \| abdominal aortic aneurysm \| 3 C0009492 \| compartment syndrome \| 3 C0037933 \| spinal disease \| 3 C0002766 \| analgesia \| 2 C0041696 \| major depression \| 2 C0038436 \| post-traumatic stress disorder \| 2 C0679466 \| cognitive deficits \| 2 C0004936 \| mental disorders \| 2 C0037933 \| spinal disorder \| 2 C0020538 \| hypertension \| 2 C1510471 \| hypovitaminosis \| 2 C0037933 \| spinal diseases \| 2 C0026846 \| muscle atrophy \| 2 C0948265 \| metabolic syndrome \| 2 C0205769 \| myxopapillary ependymoma \| 2 C0035579 \| hypovitaminosis d \| 2 C0042373 \| vascular disorders \| 1 C0026847 \| spinal muscle atrophy \| 1 C0547030 \| visual disturbances \| 1 C0036202 \| sarcoidosis \| 1 C0014118 \| endocarditis \| 1 C0042870 \| vitamin d defic \| 1 C0024796 \| marfan syndrome \| 1 C0949691 \| spondyloarthropathies \| 1 C0027765 \| neurological disorder \| 1 C0035435 \| rheumatic disease \| 1 C0029443 \| osteomyelitis \| 1 C0018916 \| hemangioma \| 1 C0023801 \| lipomatosis \| 1 C0032231 \| pleurisy \| 1 C0036310 \| scheuermann's disease \| 1 C0022972 \| myasthenic syndrome \| 1 C0242379 \| lung cancer \| 1 C0851578 \| sleep disorders \| 1 C0007222 \| cardiovascular disorders \| 1 C0042870 \| vitamin d deficiency \| 1 C0029423 \| osteochondroma \| 1 C0026764 \| myeloma \| 1 C0042164 \| uveitis \| 1 C0021775 \| intermittent claudication \| 1 C0546837 \| oesophageal cancer \| 1 C0021831 \| bowel disease \| 1 C0392548 \| cauda equina syndrome \| 1 C0042373 \| vascular disorder \| 1 C0025202 \| melanoma \| 1 C0010346 \| crohn's disease \| 1 C0013502 \| hydatid cyst \| 1 C0078981 \| arachnoid cyst \| 1 C0041326 \| tuberculous pleurisy \| 1 C0020538 \| high blood pressure \| 1 C0011849 \| diabetes mellitus \| 1 C0270629 \| epidural abscess \| 1 C0547030 \| visual disturbance \| 1 C0014544 \| epilepsy \| 1 C0030567 \| parkinson's disease \| 1 C0007789 \| cerebral palsy \| 1 C0442874 \| neuropathy \| 1 C0001430 \| adenoma \| 1 C0022972 \| lambert-eaton myasthenic syndrome \| 1 C0018920 \| cavernous hemangioma \| 1 C0035435 \| rheumatic diseases \| 1 C0149931 \| migraine \| 1 C0700594 \| radicular syndrome \| 1 C0042075 \| urological disorders \| 1 C0037317 \| sleep disturbances \| 1 C0007462 \| causalgia \| 1 C0030421 \| paraganglioma \| 1 C0037928 \| myelopathy \| 1 C0020540 \| accelerated hypertension \| 1 C0015230 \| rash \| 1 C0003486 \| aortic aneurysms \| 1 C0011860 \| type 2 diabetes mellitus \| 1 C0009447 \| common variable immunodeficiency \| 1 C0017105 \| gas gangrene \| 1 C0021390 \| inflammatory bowel disease \| 1 C0027765 \| neurological disorders \| 1 C0014859 \| esophageal cancer \| 1 C0012624 \| spondylodiscitis \| 1 C0031117 \| peripheral neuropathy \| 1 C0023798 \| lipomas \| 1 C0036205 \| pulmonary sarcoidosis \| 1 C0040053 \| thrombosis \| 1 C0162871 \| abdominal aneurysm \| 1 C0016053 \| myofascial pain syndrome \| 1 C0014121 \| infective endocarditis \| 1 C0206734 \| hemangioblastoma \| 1 C0024299 \| lymphoma \| 1
Curated Gene	Entrez_id \| Symbol \| Resource(Total Genes:1) PLAT \| 5327 \| CTD_human
Inferring Gene	(Waiting for update.)
Text Mined Gene	(Waiting for update.)
Locus	(Waiting for update.)

Disease ID	1928
Disease	back pain
Integrated Phenotype	(Waiting for update.)
Text Mined Phenotype	HPO \| Name \| Sentences' Count(Total Phenotypes:110) HP:0012531 \| Pain \| 150 HP:0000716 \| Depression \| 30 HP:0011868 \| Sciatica \| 25 HP:0008419 \| Degeneration of intervertebral disks \| 20 HP:0012532 \| Chronic pain \| 12 HP:0000939 \| Osteoporosis \| 12 HP:0001945 \| Fever \| 12 HP:0001369 \| Arthritis \| 10 HP:0002360 \| Sleep disturbance \| 9 HP:0001513 \| Obesity \| 8 HP:0003416 \| Spinal canal stenosis \| 8 HP:0002953 \| Vertebral compression fractures \| 8 HP:0100785 \| Insomnia \| 7 HP:0003302 \| Spondylolithesis \| 7 HP:0002650 \| Scoliosis \| 7 HP:0000739 \| Anxiety \| 6 HP:0002758 \| Osteoarthritis \| 6 HP:0002617 \| Aneurysmal dilatation \| 6 HP:0009763 \| Limb pain \| 5 HP:0004942 \| Aortic aneurysm \| 5 HP:0004610 \| Narrow lumbar spinal canal \| 5 HP:0002315 \| Headaches \| 5 HP:0003401 \| Paresthesia \| 4 HP:0002948 \| Fusion of vertebral bodies \| 4 HP:0003304 \| Spondylolysis \| 4 HP:0001370 \| Rheumatoid arthritis \| 4 HP:0012514 \| Lower limb pain \| 4 HP:0001824 \| Weight loss \| 4 HP:0002808 \| Gibbus deformity \| 4 HP:0005881 \| Spinal instability \| 4 HP:0002027 \| Abdominal pain \| 3 HP:0012378 \| Fatigue \| 3 HP:0003307 \| Hyperlordosis \| 3 HP:0002664 \| Neoplasia \| 3 HP:0030833 \| Neck pain \| 3 HP:0002938 \| Exaggerated lumbar lordosis \| 3 HP:0004953 \| Abdominal aortic aneurysm \| 3 HP:0002385 \| Paraparesis \| 3 HP:0001288 \| Gait disturbance \| 2 HP:0000969 \| Dropsy \| 2 HP:0002615 \| Low blood pressure \| 2 HP:0000957 \| Cafe-au-lait macules \| 2 HP:0003419 \| Low back pain \| 2 HP:0005200 \| Retroperitoneal fibrosis \| 2 HP:0100730 \| Bronchogenic cyst \| 2 HP:0003326 \| Muscle pain \| 2 HP:0100543 \| Cognitive deficits \| 2 HP:0002018 \| Nausea \| 2 HP:0003202 \| Neurogenic muscle atrophy, especially in the lower limbs \| 2 HP:0000822 \| Hypertension \| 2 HP:0002094 \| Dyspnea \| 2 HP:0002527 \| Falls \| 1 HP:0012735 \| Coughing \| 1 HP:0001257 \| Spasticity \| 1 HP:0000554 \| Uveitis \| 1 HP:0012033 \| Sacral lipoma \| 1 HP:0001762 \| Talipes equinovarus \| 1 HP:0001324 \| Muscular weakness \| 1 HP:0002017 \| Nausea and vomiting \| 1 HP:0002861 \| Melanoma \| 1 HP:0003155 \| Hyperphosphatasia \| 1 HP:0002888 \| Ependymoma \| 1 HP:0002317 \| Unsteady walk \| 1 HP:0008843 \| Hip osteoarthritis \| 1 HP:0002102 \| Pleuritis \| 1 HP:0002076 \| Migraine headaches \| 1 HP:0100520 \| Oliguria \| 1 HP:0005864 \| Pseudoarthroses \| 1 HP:0002025 \| Narrowing of anal opening \| 1 HP:0100512 \| Vitamin D deficiency \| 1 HP:0009830 \| Peripheral neuritis \| 1 HP:0100758 \| Gangrene \| 1 HP:0030431 \| Osteochondromas \| 1 HP:0002665 \| Lymphoma \| 1 HP:0030011 \| Imperforate hymen \| 1 HP:0012228 \| Tension-type headache \| 1 HP:0000016 \| Urinary retention \| 1 HP:0002647 \| Aortic dissection \| 1 HP:0030834 \| Shoulder pain \| 1 HP:0100702 \| Arachnoid cyst \| 1 HP:0002754 \| Bone infection \| 1 HP:0001250 \| Seizures \| 1 HP:0000819 \| Diabetes mellitus \| 1 HP:0001028 \| Strawberry mark \| 1 HP:0002487 \| Muscle spasms \| 1 HP:0001254 \| Lethargy \| 1 HP:0001048 \| Cavernous angioma \| 1 HP:0002013 \| Emesis \| 1 HP:0002721 \| Immunodeficiency \| 1 HP:0100280 \| Morbus Crohn \| 1 HP:0002668 \| Paragangliomas \| 1 HP:0001388 \| Joint laxity \| 1 HP:0003270 \| Distended abdomen \| 1 HP:0000159 \| Lip abnormality \| 1 HP:0000217 \| Dry mouth syndrome \| 1 HP:0006689 \| Bacterial endocarditis \| 1 HP:0003470 \| Inability to move \| 1 HP:0002355 \| Difficulty walking \| 1 HP:0005086 \| Knee osteoarthritis \| 1 HP:0100584 \| Endocarditis \| 1 HP:0100749 \| Thoracic pain \| 1 HP:0007340 \| Lower limb weakness \| 1 HP:0100021 \| Cerebral palsy \| 1 HP:0002196 \| Myelopathy \| 1 HP:0010797 \| Hemangioblastoma \| 1 HP:0009713 \| Spinal hemangioblastoma \| 1 HP:0001508 \| Weight faltering \| 1 HP:0002176 \| Spinal cord compression \| 1 HP:0004417 \| Intermittent claudication \| 1 HP:0002307 \| Sialorrhea \| 1

Disease ID	1928
Disease	back pain
Manually Symptom	(Waiting for update.)
Text Mined Symptom	(Waiting for update.)

Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)

All Snps(Total Genotypes:0)
(Waiting for update.)

GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)

GWASdb Snp Trait(Total Genotypes:0)
(Waiting for update.)

Mapped by lexical matching(Total Items:0)
(Waiting for update.)

Mapped by homologous gene(Total Items:0)
(Waiting for update.)

Chemical(Total Drugs:23)
CUI	ChemicalName	ChemicalID	CasRN	DiseaseName	DiseaseID	DirectEvidence	PubMedIDs
C0004604	amifostine	D004999	20537-88-6	back pain	MESH:D001416	marker/mechanism	16452524
C0004604	amitriptyline	D000639	50-48-6	back pain	MESH:D001416	therapeutic	7497563
C0004604	baclofen	D001418	1134-47-0	back pain	MESH:D001416	therapeutic	15066092
C0004604	bupivacaine	D002045	2180-92-9	back pain	MESH:D001416	marker/mechanism	7497563
C0004604	carisoprodol	D002328	78-44-4	back pain	MESH:D001416	therapeutic	7915729
C0004604	chlorzoxazone	D002753	95-25-0	back pain	MESH:D001416	therapeutic	7299979
C0004604	deferasirox	C415250	-	back pain	MESH:D001416	marker/mechanism	17233848
C0004604	doxycycline	D004318	564-25-0	back pain	MESH:D001416	marker/mechanism	13130401
C0004604	hydromorphone	D004091	466-99-9	back pain	MESH:D001416	therapeutic	19996237
C0004604	indinavir	D019469	150378-17-9	back pain	MESH:D001416	marker/mechanism	9679944
C0004604	lamotrigine	C047781	84057-84-1	back pain	MESH:D001416	marker/mechanism	15845756
C0004604	lidocaine	D008012	137-58-6	back pain	MESH:D001416	marker/mechanism	4305091
C0004604	methadone	D008691	76-99-3	back pain	MESH:D001416	therapeutic	16089243
C0004604	methotrexate	D008727	1959/5/2	back pain	MESH:D001416	marker/mechanism	4125793
C0004604	morphine	D009020	57-27-2	back pain	MESH:D001416	marker/mechanism	7497563
C0004604	morphine	D009020	57-27-2	back pain	MESH:D001416	therapeutic	10494374
C0004604	nortriptyline	D009661	72-69-5	back pain	MESH:D001416	marker/mechanism	20306168
C0004604	oxycodone	D010098	76-42-6	back pain	MESH:D001416	therapeutic	16669750
C0004604	paclitaxel	D017239	-	back pain	MESH:D001416	marker/mechanism	18593679
C0004604	ropinirole	C046649	91374-21-9	back pain	MESH:D001416	marker/mechanism	20461803
C0004604	tadalafil	D000068581	-	back pain	MESH:D001416	marker/mechanism	16034469
C0004604	tramadol	D014147	27203-92-5	back pain	MESH:D001416	marker/mechanism	20306168
C0004604	tramadol	D014147	27203-92-5	back pain	MESH:D001416	therapeutic	15522982

FDA approved drug and dosage information(Total Drugs:7)
DiseaseID	Drug_name	active_ingredients	strength	Dosage Form/Route	Marketing Status	TE code	RLD	RS
MESH:D001416	lamictal	lamotrigine	100MG	TABLET;ORAL	Prescription	AB	Yes	No
MESH:D001416	lamictal	lamotrigine	100MG	TABLET;ORAL	Prescription	AB	Yes	No
MESH:D001416	lamictal	lamotrigine	100MG	TABLET;ORAL	Prescription	AB	Yes	No
MESH:D001416	lamictal xr	lamotrigine	25MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	AB	Yes	No
MESH:D001416	lamictal xr	lamotrigine	25MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	AB	Yes	No
MESH:D001416	lamictal xr	lamotrigine	25MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	AB	Yes	No
MESH:D001416	exjade	deferasirox	125MG	TABLET, FOR SUSPENSION;ORAL	Prescription	AB	Yes	No

FDA labeling changes(Total Drugs:7)
DiseaseID	Pediatric_Labeling_Date	Trade_Name	Generic_Name_or_Proper_Name	Indications Studied	Label Changes Summary	Product Labeling	BPCA(B)	PREA(P)	BPCA(B) and PREA(P)	Pediatric Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	NNPS
MESH:D001416	01/17/2003	lamictal	lamotrigine	Adjunctive therapy for partial seizures	Extended indication from adults to pediatric patients e 2 years Patients aged 2 - 18 years had clearance influenced predominantly by total body weight and concurrent antiepileptic drug (AED) therapy. The oral clearance was higher, on a body weight basis, in pediatric patients than in adults Because of increased clearance in pediatrics, maintenance doses in patients weighing < 30 kg may need an increase of as much as 50% based upon clinical response Evidence shows that the inclusion of VPA in a multi-drug regimen increases the risk of serious, potentially life-threatening rash in pediatric patients Approximately 11.5% of the 1,081 pediatric patients who received the drug as adjunctive therapy in clinical trials discontinued treatment because of an AE	Labeling	B	-	-	-	GlaxoSmithKline	02/14/2007	FALSE'
MESH:D001416	8/5/2009	lamictal	lamotrigine	Adjunctive treatment for partial seizures in pediatric patients 1 24 months	Safety and effectiveness as adjunctive treatment for partial seizures were not demonstrated in a small randomized, double-blind, placebo-controlled, withdrawal study in pediatric patients 1 - 24 months Immediate release tablets were associated with an increased risk for infectious adverse reactions including bronchiolitis, bronchitis, ear infection, eye infection, otitis externa, pharyngitis, urinary tract infection, and viral infection (Lamictal 37%, Placebo 5%), and respiratory adverse reactions including nasal congestion, cough, and apnea. (Lamictal 26%, Placebo 5%)	Labeling	B	-	-	-	GlaxoSmithKline	02/14/2007	FALSE'
MESH:D001416	05/18/2015	lamictal	lamotrigine	Maintenance treatment of bipolar disorder	Safety and efficacy for the maintenance treatment of bipolar disorder were not established in a double-blind, placebo-controlled trial that evaluated 301 pediatric patients aged 10 to 17 Information on clinical trial and adverse reactions Postmarketing study	Labeling	-	P	-	-	GlaxoSmithKline	-	FALSE
MESH:D001416	05/29/2009	lamictal xr	lamotrigine	Adjunctive therapy for partial onset seizures in patients e13 years of age	Extended release tablets are indicated as adjunctive therapy for partial onset seizures with or without secondary generalization in patients e13 years Safety and effectiveness of extended release tablets for any use in patients below the age of 13 have not been established Information on adverse event profile, and clinical studies New dosage form	Labeling	-	P	-	-	GlaxoSmithKline	-	FALSE'
MESH:D001416	01/29/2010	lamictal xr	lamotrigine	Adjunctive therapy for Primary Generalized Tonic-Clonic seizures	New indication for adjunctive therapy for primary generalized tonic-clonic seizures in patients e 13 years of age Safety and effectiveness for any use in patients < 13 years have not been established Information on dosing, adverse reactions, and clinical studies	Labeling	-	P	-	-	GlaxoSmithKline	-	FALSE'
MESH:D001416	04/25/2011	lamictal xr	lamotrigine	Monotherapy in patients 13 years of age and older with partial seizures who are receiving therapy with a single antiepileptic drug (AED)	Approved for conversion to monotherapy in patients e13 years of age with partial seizures receiving treatment with a single antiepileptic drug (AED).Safety and effectiveness have not been established (1) as initial monotherapy or (2) for simultaneous conversion to monotherapy from two or more concomitant AEDsInformation on conversion to monotherapy, adverse reactions, clinical trialNew indication	Labeling	-	P	-	-	GlaxoSmithKline	-	FALSE'
MESH:D001416	01/23/2013	exjade	deferasirox	Treatment of chronic iron overload in patients with non-transfusion dependent thalassemia	Approved for use in 10 years and older for NTDT Safety and effectiveness have not been established in pediatric patients less than 10 years Information on dosing, adverse reactions in adults and pediatric patients, and clinical trials New indication	Labeling	-	P	-	-	Novalar Pharmaceuticals, Inc.	-	FALSE'